|
Surrozen, Inc. (SRZN): Marketing Mix [Jan-2025 Updated]
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Surrozen, Inc. (SRZN) Bundle
Surrozen, Inc. (SRZN) is revolutionizing regenerative medicine through cutting-edge Wnt pathway technology, offering groundbreaking potential in treating complex gastrointestinal and liver diseases. By harnessing proprietary monoclonal antibody therapeutics, this innovative South San Francisco-based biotech company is positioning itself at the forefront of tissue repair research, promising transformative solutions for patients and significant value for investors eager to explore the next frontier of medical innovation.
Surrozen, Inc. (SRZN) - Marketing Mix: Product
Regenerative Therapeutics Development
Surrozen, Inc. focuses on developing novel regenerative therapeutics targeting the Wnt pathway for tissue repair. The company's product portfolio is strategically designed to address unmet medical needs in gastrointestinal and liver diseases.
| Product Category | Technology Platform | Target Indication | Development Stage |
|---|---|---|---|
| Monoclonal Antibody Therapeutics | Proprietary Wnt Pathway Modulation | Gastrointestinal Diseases | Preclinical/Clinical |
| Tissue Regeneration Candidates | Antibody Technology | Liver Diseases | Early-Stage Development |
Proprietary Technology Platform
The company utilizes a specialized monoclonal antibody technology to modulate Wnt signaling, which is critical for tissue regeneration and repair.
- Unique antibody design targeting Wnt pathway
- Precision modulation of tissue repair mechanisms
- Potential application across multiple disease areas
Product Pipeline
| Product Candidate | Therapeutic Area | Mechanism | Current Status |
|---|---|---|---|
| SRZ-737 | Gastrointestinal Disorders | Wnt Pathway Modulation | Preclinical Development |
| SRZ-272 | Liver Regeneration | Tissue Repair Activation | Investigational Stage |
Key Product Characteristics
- Innovative Approach: Targeting Wnt signaling for tissue regeneration
- Precision Medicine: Monoclonal antibody-based therapeutics
- Versatile Platform: Potential applications in multiple disease contexts
Surrozen, Inc. (SRZN) - Marketing Mix: Place
Headquarters and Primary Location
Surrozen, Inc. is headquartered at 348 Oyster Point Boulevard, South San Francisco, California 94080.
Geographic Distribution Channels
| Region | Distribution Strategy | Current Status |
|---|---|---|
| United States | Primary market focus | Active clinical development |
| Europe | Potential expansion | Preliminary partnership discussions |
| Asia-Pacific | Future market consideration | Initial research phase |
Research and Development Ecosystem
- Primary R&D operations located in Bay Area biotech corridor
- Proximity to research institutions like UCSF, Stanford University
- Active collaboration with academic research centers
Clinical Trial Geographic Expansion
| Clinical Trial Sites | Number of Locations | Therapeutic Areas |
|---|---|---|
| United States | 12 sites | Regenerative medicine |
| Canada | 3 sites | Liver and gastrointestinal diseases |
Pharmaceutical Market Targeting
Primary Market Focus: United States healthcare system, with an emphasis on specialized regenerative medicine markets.
Distribution Strategy
- Direct engagement with specialized medical centers
- Potential partnerships with pharmaceutical distributors
- Strategic licensing agreements for global market access
Surrozen, Inc. (SRZN) - Marketing Mix: Promotion
Presenting Research Findings at Scientific Conferences and Medical Symposia
Surrozen, Inc. participated in the following key scientific events in 2023-2024:
| Conference | Date | Location | Presentations |
|---|---|---|---|
| American Society of Gene & Cell Therapy Annual Meeting | May 2023 | Boston, MA | 2 scientific poster presentations |
| Liver Meeting by AASLD | November 2023 | Boston, MA | 1 oral presentation on WNT pathway research |
Engaging with Potential Investors through Biotech Investor Presentations
Investor engagement activities in 2023-2024:
- Participated in 7 investor conferences
- Conducted 42 one-on-one investor meetings
- Hosted 3 virtual investor webinars
Utilizing Scientific Publications to Communicate Technological Advancements
Publication metrics for 2023:
| Publication Type | Number | Impact Factor |
|---|---|---|
| Peer-reviewed journal articles | 3 | Ranging from 5.2 to 8.7 |
| Conference abstracts | 5 | N/A |
Leveraging Digital Platforms to Communicate Company Progress and Pipeline Updates
Digital communication statistics:
- LinkedIn followers: 4,287
- Twitter/X followers: 1,653
- Website unique monthly visitors: 12,500
- Press releases issued: 9
Networking with Potential Pharmaceutical Licensing and Collaboration Partners
Collaboration engagement in 2023:
| Activity | Number |
|---|---|
| Initial partnership discussions | 12 |
| Non-disclosure agreements signed | 5 |
| Advanced collaboration talks | 3 |
Surrozen, Inc. (SRZN) - Marketing Mix: Price
Financial Overview
As of Q4 2023, Surrozen, Inc. reported the following financial metrics:
| Financial Metric | Value |
|---|---|
| Market Capitalization | $43.2 million |
| Cash and Cash Equivalents | $35.6 million |
| Stock Price (NASDAQ) | $1.47 per share |
| Research and Development Expenses | $18.3 million annually |
Funding Strategy
Surrozen's pricing and financial approach is characterized by the following key elements:
- Venture capital funding rounds totaling $72.5 million to date
- Public market financing through NASDAQ listing
- Strategic partnerships with potential pharmaceutical companies
Stock Performance Metrics
| Performance Indicator | Value |
|---|---|
| 52-Week Stock Price Range | $0.89 - $2.35 |
| Current Trading Volume | 125,000 shares daily average |
| Short Interest | 12.3% of float |
Clinical Development Investment
Surrozen's pricing strategy is directly tied to its therapeutic pipeline investment:
- Committed $15.7 million to Wnt pathway therapeutic research
- Focused on rare disease and regenerative medicine programs
- Potential future revenue dependent on FDA approval milestones
Investor Funding Breakdown
| Funding Source | Amount | Percentage |
|---|---|---|
| Venture Capital | $52.4 million | 72.4% |
| Public Market Offering | $12.6 million | 17.4% |
| Strategic Partnerships | $7.5 million | 10.2% |